ATLANTA -- Disease progression is less likely in patients with rheumatoid arthritis (RA) who haven't responded to methotrexate alone if this disease-modifying drug is continued when treatment with the biologic drug etanercept (Enbrel) is initiated, according to research presented here.
Significant differences in joint erosion scores were seen after two years of combined etanercept plus methotrexate compared with etanercept alone (−0.5 versus 3.1, P=0.045), reported Hideto Kameda, MD, of Keio University in Tokyo, and colleagues at the annual meeting of the American College of Rheumatology (ACR).
To read the entire article: http://www.medpagetoday.com/Rheumatology/Arthritis/23300